MeSH tree: C23.550.291.656
The U.S. Food and Drug Administration has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).
Aug 21, 2025
0
9
Spinal muscular atrophy (SMA) is a rare genetic condition that causes progressive muscle weakness, which, when untreated, prevents infants with the most severe form from gaining motor development—never gaining the ability ...
Aug 14, 2025
0
83
A Peter Mac-initiated clinical trial suggests a way to dramatically improve outcomes in patients with high-risk forms of large B-cell lymphoma, who otherwise have a 50% chance of cure from conventional therapy.
Jun 19, 2025
0
26
The Very Early Diagnosis of Systemic Sclerosis (VEDOSS) criteria identify red flags as puffy fingers, abnormal nailfold capillaroscopy, and specific autoantibodies in patients with Raynaud's phenomenon as a very early disease ...
Jun 12, 2025
0
13
Researchers from the University of California San Diego School of Medicine have discovered that children living with multiple sclerosis (MS) show signs of accelerated biological aging, even in their teenage years. The research, ...
Jun 9, 2025
0
18
Recent results from the NRG-NSABP B-51/RTOG 1304 clinical study showed that the addition of regional nodal irradiation (RNI) does not decrease the rates of invasive breast cancer recurrence in patients whose positive axillary ...
Jun 5, 2025
0
15
Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A less intensive, reduced ...
Jun 2, 2025
0
21
A new trial of patients with advanced rectal cancer has found that the addition of immunotherapy treatment alongside extended radiotherapy led to better rates of remission.
May 9, 2025
0
25
Triple-negative breast cancer (TNBC) is an aggressive form of the disease that accounts for 15% of all breast cancer cases. Black women are twice as likely as white women to be diagnosed with TNBC and 28% more likely to die ...
Feb 18, 2025
0
15
SOLARIS (Alliance A021703), a multicenter, double-blind, randomized Phase III clinical trial led by Dana-Farber Cancer Institute researchers and conducted across several hundred cancer centers in the U.S. tested the addition ...
Sep 16, 2024
0
57
